Early Intervention with Donanemab Cuts Alzheimer’s Progression Risk by 27% – Breakthrough Study Reveals
Groundbreaking results from the TRAILBLAZER-ALZ 2 trial show that donanemab doesn't just mask symptoms—it fundamentally changes the disease's trajectory, saving...
New Blood Test Shows Strong Potential for Early Detection of Multiple Cancers, Major Study Finds
In research published this week, scientists reported that a new type of multi-cancer early detection (MCED) blood test — which...
FEATURED POST
